Relapsed/Refractory Archives

June 18, 2025

Outcomes After Discontinuing BTKi Due to Adverse Effects

Patients with CLL who have to discontinue a BTK inhibitor due to adverse side effects can still experience prolonged remissions without therapy.

June 18, 2025

Rocbrutinib – a Dual Covalent and Non-Covalent BTK Inhibitor

Though it is still early on, rocbrutinib appears to be effective in CLL patients with prior BTKi resistance mutations, and it is generally well-tolerated.

May 28, 2025

Duvelisib Plus Venetoclax for Relapsed CLL

The time-limited combination of duvelisib plus venetoclax was effective for treating relapsed / refractory CLL, but it also had significant side effects.

May 28, 2025

Long-Term Outcomes After CAR-T Therapy for CLL

CAR-T therapy can provide very long remissions in a subset of patients with relapsed / refractory CLL who responded for at least one year.

May 28, 2025

A Noncovalent LYN / BTK Dual Inhibitor for Relapsed B Cell Cancers

DZD8586 is an experimental noncovalent LYN / BTK dual inhibitor that is being tested in patients with relapsed / refractory B cell cancers.

May 5, 2025

Venetoclax for Relapsed CLL After Covalent BTK Inhibitors

Some patients who receive venetoclax for relapsed CLL after prior treatment with a covalent BTKi only benefit for 2-3 years, which is shorter than expected.

April 14, 2025

Making CAR-T Cells Inside the Body (In Vivo) to Treat CLL

CAR-T is an effective but underused option in cancer. Successful engineering of CAR-T cells in vivo in nonhuman primates has now been achieved.

April 9, 2025

Pirtobrutinib for Relapsed CLL After Covalent BTKi Therapy

Pirtobrutinib provides longer progression-free survival and is safer than idelalisib-rituximab and bendamustine-rituximab for treating relapsed CLL.

February 20, 2025

Promising Results in Difficult-to-Treat CLL with Epcoritamab

Epcoritamab, a novel bispecific antibody monotherapy, showed strong results in relapsed / refractory high-risk CLL patients.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Relapsed/Refractory

Outcomes After Discontinuing BTKi Due to Adverse Effects

Rocbrutinib – a Dual Covalent and Non-Covalent BTK Inhibitor

Duvelisib Plus Venetoclax for Relapsed CLL

Long-Term Outcomes After CAR-T Therapy for CLL

A Noncovalent LYN / BTK Dual Inhibitor for Relapsed B Cell Cancers

Venetoclax for Relapsed CLL After Covalent BTK Inhibitors

Making CAR-T Cells Inside the Body (In Vivo) to Treat CLL

Pirtobrutinib for Relapsed CLL After Covalent BTKi Therapy

Promising Results in Difficult-to-Treat CLL with Epcoritamab

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT